TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24037083

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg orally once daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 41
Study: 24037550

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (Zostavax)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (10 subjects ≥ age 50 years)
Number of subjects: 10
Study: 24037801

Group type: EXPERIMENTAL
Intervention: Carmustine wafers (CW)
Number of subjects: 59
Study: 24037866

Group type: EXPERIMENTAL
Intervention: Community-directed treatment (ComDT) added to health facility (HF) approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health facility (HF) approach alone
Number of subjects: 0
Study: 24037867

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 613

Group type: COMPARATOR
Intervention: Non-recommended antimalarials
Number of subjects: 613

Group type: COMPARATOR
Intervention: Laboratory diagnosis
Number of subjects: 613
Study: 24038364

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine/pyrimethamine (IPTi-SP)
Number of subjects: 29000

Group type: COMPARATOR
Intervention: Comparison areas (not receiving IPTi-SP)
Number of subjects: 29000
Study: 24039230

Group type: EXPERIMENTAL
Intervention: Chronic rhinosinusitis (CRS)
Number of subjects: 70000000

Group type: EXPERIMENTAL
Intervention: Inflammatory disease process
Number of subjects: 70000000

Group type: EXPERIMENTAL
Intervention: Sleep physiology regulation
Number of subjects: 70000000
Study: 24040920

Group type: EXPERIMENTAL
Intervention: Information from the general practitioner about high cholesterol and risk of cardiovascular disease
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Positive mindset as a strategy to lower risk of high cholesterol
Number of subjects: 14
Study: 24041790

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HIV-infected women with noncalcified coronary plaque
Number of subjects: 60
Study: 24042076

Group type: EXPERIMENTAL
Intervention: Children with autism following a restricted diet
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Children with autism not following a restricted diet
Number of subjects: 69

Group type: COMPARATOR
Intervention: Typically developing children (TYP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Children with developmental delay
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Children with autism (AUT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Children with autism (AUT) with intentional diet restrictions
Number of subjects: 69
Study: 24042386

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study: 24042540

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT at 3 months
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Probability of being free of local recurrence
Number of subjects: 89
Study: 24043379

Group type: EXPERIMENTAL
Intervention: Catheter-over-needle assembly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional catheter assembly
Number of subjects: 0
Study: 24044794

Group type: EXPERIMENTAL
Intervention: Cardiac comorbidity
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Model with cardiac comorbidity and other factors
Number of subjects: 259
Study: 24044880

Group type: EXPERIMENTAL
Intervention: Social support from family and friends
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Smoking-related attitudinal variables
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: General social support (ISEL)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: SSQ scores
Number of subjects: 247
Study: 24045453

Group type: EXPERIMENTAL
Intervention: Laparoscopic total fundoplication (LTF)
Number of subjects: 188
Study: 24045500

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24045608

Group type: EXPERIMENTAL
Intervention: Intravenous amantadine sulfate 200 mg
Number of subjects: 6
Study: 24046475

Group type: EXPERIMENTAL
Intervention: Renal optimization strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 24047338

Group type: EXPERIMENTAL
Intervention: Relative volume above higher SUV (80%)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Metabolic tumor volume (MTV) based on volumes above SUV of 3, 40% and 50% of maximum SUV
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Maximum and peak SUV
Number of subjects: 220
Study: 24047768

Group type: EXPERIMENTAL
Intervention: Positioning left-sided double-lumen tubes (DLTs) using minimum PIP differences
Number of subjects: 102

Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 102
Study: 24047918

Group type: EXPERIMENTAL
Intervention: Adherence to the 2006 American Heart Association Diet and Lifestyle Recommendations (AHA-DLR)
Number of subjects: 933
Study: 24047921

Group type: EXPERIMENTAL
Intervention: INTERSALT equations with morning specimens
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: INTERSALT equations with afternoon specimens
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: INTERSALT equations with evening specimens
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Tanaka equations with overnight specimens
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Mage equations with overnight specimens
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Tanaka equations among females
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Mage equations among races other than black
Number of subjects: 407
Study: 24048361

Group type: EXPERIMENTAL
Intervention: Dermatologist-determined Fitzpatrick skin type (FST)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Participant-determined Fitzpatrick skin type (FST)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Participant responses to burning
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Participant responses to tanning
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Spectrophotometry measurements assessing FST
Number of subjects: 270
Study: 24048627

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (50.4 Gy in 28 fractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib and irradiation
Number of subjects: 0
Study: 24048673

Group type: EXPERIMENTAL
Intervention: GLP-1 co-infusion during hyperglycaemic clamps
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GIP co-infusion during hyperglycaemic clamps
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline co-infusion during hyperglycaemic clamps
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Postoperative OGTT
Number of subjects: 11
Study: 24049022

Group type: EXPERIMENTAL
Intervention: hHGF measurement on admission
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: hHGF measurement 24 hours later
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: hHGF increase
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal hHGF concentration
Number of subjects: 73
Study: 24049718

Group type: EXPERIMENTAL
Intervention: Argus II epiretinal prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full field stimulus light threshold measured using the Espion D-FST test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Macular contact of the array
Number of subjects: 0
Study: 24050953

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily orally until unacceptable toxicity or disease progression
Number of subjects: 40
Study: 24050955

Group type: EXPERIMENTAL
Intervention: Post-diagnostic β-blocker use
Number of subjects: 4794

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4794

Group type: COMPARATOR
Intervention: Control group (no β-blocker use)
Number of subjects: 4794
Study: 24051172

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus a taxane (docetaxel or paclitaxel)
Number of subjects: 41
Study: 24051483

Group type: EXPERIMENTAL
Intervention: Fortified human breast milk (fHBM)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Human breast milk (HBM)
Number of subjects: 162
Study: 24051744

Group type: EXPERIMENTAL
Intervention: 99mTc-tilmanocept
Number of subjects: 20

Group type: COMPARATOR
Intervention: SPECT/CT
Number of subjects: 20
Study: 24052462

Group type: EXPERIMENTAL
Intervention: Once-monthly continuous erythropoietin receptor activator (CERA)
Number of subjects: 348
Study: 24053191

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel, 120 mg every 28 days over ≤92 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel
Number of subjects: 30
Study: 24053517

Group type: EXPERIMENTAL
Intervention: HDP-LGI diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: NDP-LGI diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 10
Study: 24053656

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice-daily for 21 days, followed by 20 mg once-daily)
Number of subjects: 8282

Group type: COMPARATOR
Intervention: Standard-therapy (enoxaparin 1.0 mg/kg twice-daily and warfarin or acenocoumarol)
Number of subjects: 8282

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8282

Group type: COMPARATOR
Intervention: Standard-therapy
Number of subjects: 8282
Study: 24055176

Group type: EXPERIMENTAL
Intervention: Monotherapy with various treatments for T2DM
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measures using EQ-5D and ADDQoL
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Fear of hypoglycemia measured by HFS-II
Number of subjects: 751
Study: 24055443

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer-coated sirolimus-eluting stent
Number of subjects: 0
Study: 24055823

Group type: EXPERIMENTAL
Intervention: Allogeneic anti-CD19-CAR T cells
Number of subjects: 10
Study: 24056237

Group type: EXPERIMENTAL
Intervention: High functioning ASD group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Neurotypical (NT) group
Number of subjects: 37
Study: 24056477

Group type: EXPERIMENTAL
Intervention: Enhanced hand hygiene promotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal MRSA screening with contact precautions and decolonisation (intranasal mupirocin and chlorhexidine bathing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of enhanced hand hygiene and MRSA screening with contact precautions and decolonisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRSA screening, contact precautions and decolonisation in clean surgery wards
Number of subjects: 0
Study: 24057266

Group type: EXPERIMENTAL
Intervention: Clinic-based follow-up visits
Number of subjects: 209

Group type: COMPARATOR
Intervention: Remote monitoring strategy
Number of subjects: 209
Study: 24057647

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 16
Study: 24058078

Group type: EXPERIMENTAL
Intervention: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²) + Bare metal stent (BMS)
Number of subjects: 120
Study: 24059479

Group type: EXPERIMENTAL
Intervention: Balanced solution (BS) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unbalanced solution (UBS) group
Number of subjects: 40
Study: 24059787

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24062394

Group type: EXPERIMENTAL
Intervention: Liver radiotherapy (RT)
Number of subjects: 41
Study: 24062399

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for cancer
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: High baseline Geriatric Depression Scale (GDS15)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Low Instrumental Activities of Daily Living (IADL) scores
Number of subjects: 364
Study: 24062895

Group type: EXPERIMENTAL
Intervention: NT-proBNP testing
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels below median (5000 pg/ml)
Number of subjects: 470
Study: 24063518

Group type: EXPERIMENTAL
Intervention: Cross-sectional assessment including medical evaluation, neuropsychological test battery, anthropometric measurements, social and lifestyle interview, blood analyses, and storage of blood samples.
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Longitudinal survey to be conducted two and four years after initial data collection.
Number of subjects: 1644
Study: 24063569

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (self-reported inhaling ≥ 50 puffs per week since ≥ 6 months)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Traditional cigarettes (≥ 1 per day since ≥ 6 months)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Mixed users (both electronic and traditional cigarettes, ≥ 1 per day since ≥ 6 months)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes
Number of subjects: 1500
Study: 24063698

Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle
Number of subjects: 19
Study: 24063735

Group type: EXPERIMENTAL
Intervention: TG1042 (adenovirus vector expressing human interferon-gamma)
Number of subjects: 0
Study: 24063848

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 846
Study: 24064228

Group type: EXPERIMENTAL
Intervention: Cooling initiated with surface cooling pads, followed by 1000-2000 mL of cold saline at hospital arrival and endovascular cooling in the catheterisation laboratory.
Number of subjects: 19
Study: 24064318

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT) to a prescribed dose of 38.5 Gy in 10 fractions.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT).
Number of subjects: 48
Study: 24065066

Group type: EXPERIMENTAL
Intervention: Higher dietary vitamin E intake
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lower dietary vitamin E intake
Number of subjects: 205
Study: 24065152

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin therapy (weight gain >4%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin therapy (weight gain no or little)
Number of subjects: 0
Study: 24065445

Group type: EXPERIMENTAL
Intervention: Excimer laser-assisted retrieval
Number of subjects: 100
Study: 24066670

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 100 mg/kg after 2 Gy radiation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP) at 5 mg/kg after 2 Gy radiation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 100 mg/kg after 0.5 Gy radiation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP) at 5 mg/kg after 0.5 Gy radiation
Number of subjects: 2
Study: 24067666

Group type: EXPERIMENTAL
Intervention: Integrated model for the management of SAM (IM-SAM)
Number of subjects: 2740
Study: 24068445

Group type: EXPERIMENTAL
Intervention: Iterative Doppler AVD optimization
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Blinded selection of optimum AVD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Unblinded selection of optimum AVD
Number of subjects: 50
Study: 24068762

Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing intervention (10 units of insulin glargine at bedtime, adjusted by increments of 1 unit daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pharmacist prescribing intervention
Number of subjects: 100
Study: 24069180

Group type: EXPERIMENTAL
Intervention: WINROP (postnatal weight-gain algorithm)
Number of subjects: 707
Study: 24069533

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab treatment
Number of subjects: 144
Study: 24070065

Group type: EXPERIMENTAL
Intervention: aPC infusion (24 mcg/kg/h for 96 hours)
Number of subjects: 22

Group type: COMPARATOR
Intervention: no-aPC group
Number of subjects: 22
Study: 24070658

Group type: EXPERIMENTAL
Intervention: Clinician gestalt estimate for acute coronary syndrome
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Clinician gestalt estimate for pulmonary embolism
Number of subjects: 840

Group type: COMPARATOR
Intervention: Attribute matching for acute coronary syndrome
Number of subjects: 840

Group type: COMPARATOR
Intervention: Attribute matching for pulmonary embolism
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for clinician gestalt (acute coronary syndrome)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Receiver operating characteristic curve for attribute matching (acute coronary syndrome)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve for clinician gestalt (pulmonary embolism)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Receiver operating characteristic curve for attribute matching (pulmonary embolism)
Number of subjects: 840
Study: 24070982

Group type: EXPERIMENTAL
Intervention: EEG performed on patients with AMS
Number of subjects: 259
Study: 24070998

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging of embryos cultured for 6 days in a time-lapse incubator (EmbryoScope(™)), with automated image recording every 20 min.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging of embryos cultured for 6 days in a time-lapse incubator (EmbryoScope(™)).
Number of subjects: 20
Study: 24073008

Group type: EXPERIMENTAL
Intervention: Ayurvedic treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional standard care
Number of subjects: 32
Study: 24074142

Group type: EXPERIMENTAL
Intervention: SootherMask® designed from 3D anthropometric data
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Average masks from small, medium, and large clusters
Number of subjects: 271
Study: 24075057

Group type: EXPERIMENTAL
Intervention: Expeditioners
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sherpas
Number of subjects: 25
Study: 24075467

Group type: EXPERIMENTAL
Intervention: Blood pressure below the limits of cerebral autoregulation during cardiopulmonary bypass
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation monitoring
Number of subjects: 450
Study: 24075534

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.2 mg/m(2) and idarubicin 8 mg/m(2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bortezomib 0.8 mg/m(2) and idarubicin 10 mg/m(2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m(2) and idarubicin 10 mg/m(2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bortezomib and idarubicin combination
Number of subjects: 20
Study: 24075648

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 484

Group type: COMPARATOR
Intervention: No lifestyle intervention
Number of subjects: 484
Study: 24075891

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (CE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Small-bowel follow-through (SBFT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ileocolonoscopy
Number of subjects: 80
Study: 24076529

Group type: EXPERIMENTAL
Intervention: NeoChord DS1000 system (NeoChord, Inc.)
Number of subjects: 30
Study: 24076532

Group type: EXPERIMENTAL
Intervention: Left atrial volume index (LAVi) ≥32 ml/m²
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: LAVi ≥32 ml/m²
Number of subjects: 305

Group type: COMPARATOR
Intervention: LAVi <32 ml/m²
Number of subjects: 305
Study: 24076699

Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid gel (mean of 163 ml per buttock)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid gel
Number of subjects: 8
Study: 24077565

Group type: EXPERIMENTAL
Intervention: Taste-sensitive region of the caudal insula responding to food images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rostral insula
Number of subjects: 0
Study: 24077845

Group type: EXPERIMENTAL
Intervention: Acquired ASXL1 mutations in patients with GATA2 deficiency
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GATA2 deficiency patients with acquired ASXL1 mutation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Number of subjects: 48
Study: 24077846

Group type: EXPERIMENTAL
Intervention: Imatinib plus sequential chemotherapy followed by autologous stem cell transplantation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Allogeneic stem cell transplantation
Number of subjects: 58
Study: 24077916

Group type: EXPERIMENTAL
Intervention: Neratinib (200 mg/day) with trastuzumab (4 mg/kg IV loading dose, then 2 mg/kg IV weekly) and paclitaxel (80 mg/m2 IV days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neratinib (120 up to 240 mg/day) with trastuzumab and paclitaxel
Number of subjects: 21
Study: 24078868

Group type: EXPERIMENTAL
Intervention: Individualized texting for adherence building (iTAB)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Active comparison condition
Number of subjects: 29
Study: 24078876

Group type: EXPERIMENTAL
Intervention: HEM-AVERT Perianal Stabilizer
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 98
Study: 24079262

Group type: EXPERIMENTAL
Intervention: Physical examination to guide fluid therapy
Number of subjects: 28
Study: 24079306

Group type: EXPERIMENTAL
Intervention: HRP2-based RDT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LDH-based RDT
Number of subjects: 53

Group type: COMPARATOR
Intervention: Giemsa-stained blood smear
Number of subjects: 53

Group type: COMPARATOR
Intervention: Acridine orange-stained blood smear
Number of subjects: 53

Group type: COMPARATOR
Intervention: Real-time PCR
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall recurrent infections
Number of subjects: 53
Study: 24079475

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG) measurement
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ultrasound dating scans
Number of subjects: 131

Group type: COMPARATOR
Intervention: Last menstrual period (LMP) estimates
Number of subjects: 131